Chicago Partners Investment Group LLC Has $45,000 Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Chicago Partners Investment Group LLC cut its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 48.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,066 shares of the biopharmaceutical company’s stock after selling 14,433 shares during the period. Chicago Partners Investment Group LLC’s holdings in Esperion Therapeutics were worth $45,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Private Portfolio Partners LLC acquired a new stake in Esperion Therapeutics during the fourth quarter worth approximately $30,000. PSI Advisors LLC increased its holdings in shares of Esperion Therapeutics by 161.5% during the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 10,500 shares during the period. Spire Wealth Management increased its holdings in shares of Esperion Therapeutics by 69.2% during the fourth quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 7,267 shares during the period. Foundations Investment Advisors LLC bought a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $60,000. Finally, Azimuth Capital Investment Management LLC bought a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $66,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $2.72 on Wednesday. Esperion Therapeutics, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $3.40. The firm has a market capitalization of $515.33 million, a P/E ratio of -2.75 and a beta of 1.00. The company’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $2.36.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.42. The company had revenue of $137.74 million during the quarter, compared to analyst estimates of $53.11 million. On average, analysts expect that Esperion Therapeutics, Inc. will post -0.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ESPR shares. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday, May 21st. StockNews.com cut shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, May 7th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $12.00.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.